Memorial Sloan Kettering Cancer Center presents:

2nd International Symposium on

Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy

OCTOBER 11-12, 2019

ZUCKERMAN RESEARCH CENTER
NEW YORK, NY

Memorial Sloan Kettering Cancer Center
Today, more than 10,000 hematopoietic cell transplantations (HCTs) are performed yearly in the United States as treatment for more than 70 life threatening illnesses including cancers, genetic disorders, and other diseases. Also, given the shift toward cellular therapies in the field of HCT, the number of patients treated with these novel biologic agents is rapidly increasing.

Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, pharmacists, data managers, and other healthcare professionals who provide care for patients undergoing HCT and cellular therapies.

**Educational Objectives**

- Understand the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Identify best practices to prevent and treat toxicities and symptom burden after HCT and cellular therapy to improve the patient experience and reduce non-relapse mortality.
- Understand how to approach prevention and treatment of toxicities and symptom burden in unique HCT and cellular therapy patient populations.

**Call for Abstracts**

Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted. Top awarded abstracts will receive a travel grant tied to attending this symposium.

**Submission Deadline:** September 14, 2019

**Live Simulcast Available**

Visit mskcc.org/toxicities for more information or to register.
FACULTY

Invited Course Faculty

**Keynote Speaker**
- Andrea Bacigalupo, MD
  Poli Clinico A. Gemelli
  Rome, Italy

Department of Medicine Grand Rounds Lecturer
- George McDonald, MD
  Fred Hutchinson Cancer Research Center

Rajni Agarwal-Hashmi, MD
Stanford

Andrew Artz, MD, MS
City of Hope

Ami Bhatt, MD, PhD
Stanford

Sita Bhella, MEd, MD
University of Toronto

Kira Bona, MD, MPH
Dana Farber/Boston Children's

Chris Bredeson, MD, MSc, FRCP
Ottawa Hospital Research Institute
  Ottawa, ON, Canada

Mitchell Cairo, MD
New York Medical College

Louis Cohen, MD
M Sheba Medical Center

Christopher Dandoy, MD, MS
Cincinnati Children’s Hospital Medical Center

Christine Duncan, MD
Dana Farber/Boston Children’s

Areej R. El-Jawahri, MD
Massachusetts General Hospital

Mareike Frick, MD
Charite UMC
  Berlin, Germany

Theresa Hahn, PhD
Roswell Park Comprehensive Cancer Center

MSK Course Faculty

- JJ Boelens, MD, PhD
- Christian Otto, MD, MMSn, DABFM

Keynote Speaker
- Bronwen E Shaw, MD, PhD
  Medical College of Wisconsin

Department of Medicine Grand Rounds
- Melissa Hudson, MD
  St. Jude Children's Research Hospital
- Richard J. Jones, MD
  Johns Hopkins
- Benjamin Laskin, MD, MS
  Children's Hospital of Philadelphia
- Hillard Lazarus, MD, FACP
  University Hospitals Cleveland Medical Center
- John K. Lin, MD
  Perelman School of Medicine at the University of Pennsylvania
- Caroline Lindemans, MD, PhD
  UMC Utrecht
  Utrecht, Netherlands
- Thomas Luft, MD, PhD
  Heidelberg University Hospital
  Heidelberg, Germany
- Kerry McMillen, MS, RD, CSO, FAND
  Fred Hutchinson Cancer Research Center
- Pawel Muranski, MD
  Columbia University Medical Center
- Stefan Nierkens, PhD
  UMC Utrecht
  Utrecht, Netherlands
- Pavan Reddy, MD
  University of Michigan
  Comprehensive Cancer Center
- Karen Syrjala, PhD
  Fred Hutchinson Cancer Research Center

Gastrointestinal Toxicity, Nutrition and the Microbiome
MODERATORS: David Faleck, MD and Kenneth R. Cooke, MD

DAY 1 · FRIDAY, OCTOBER 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>7:50 AM</td>
<td>Welcome, Opening Remarks and Conference Overview</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Department of Medicine Grand Rounds</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>GI and Hepatobiliary Complications of HCT</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parenteral?</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Accelerated Functional Aging and Sarcopenia After HCT</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Association of the Pulmonary Virioma and Post-HCT Pulmonary Toxicities</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapies</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicities</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Harnessing Biotech Innovations and Telemedicine Potential in HCT and Cellular Therapies</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>Using Dynamic Scoring Systems to Predict and Prevent NRM After HCT</td>
</tr>
</tbody>
</table>

Lunch Breakout Seminars
- Harnessing Biotech Innovations and Telemedicine Potential in HCT and Cellular Therapies
  **ROOM 136**
  MODERATORS: William A. Wood, MD
  Michael Scordo, MD
  SPEAKERS: Chris Bredeson, MD, MSc, FRCPC
  Christian Otto, MD, MMSn, DABFM

- Using Dynamic Scoring Systems to Predict and Prevent NRM After HCT
  **ROOM 105**
  MODERATORS: Miguel Perales, MD
  Sergio A. Giralt, MD
  SPEAKERS: Thomas Luft, MD, PhD
  Andrea Bacigalupo, MD
### Psychosocial, Quality of Life, and Caring for Unique Populations in HCT and Cellular Therapies

**MODERATORS:** Maria Cancio, MD and William A. Wood, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 pm</td>
<td>Chronic Disease Burden in Survivors of Childhood HCT</td>
<td>Melissa Hudson, MD</td>
</tr>
<tr>
<td>2:35 pm</td>
<td>Toxicities and Outcomes in the Geriatric Patient After HCT and Cellular Therapies</td>
<td>Andrew Artz, MD, MS</td>
</tr>
<tr>
<td>2:55 pm</td>
<td>“It Takes a Village” – Impact of Psychosocial Risk on HCT Outcomes</td>
<td>Karen Syrjala, PhD</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Patient-Reported Outcomes and Symptom Burden After CAR T Cell Therapy</td>
<td>Navneet Majhail, MD, MS</td>
</tr>
<tr>
<td>3:35 pm</td>
<td>End-of-Life Care in HCT: What Do HCT Physicians Think About Palliative Care?</td>
<td>Areej R. El-Jawahri, MD</td>
</tr>
<tr>
<td>3:55 pm</td>
<td>Q&amp;A with Speakers</td>
<td></td>
</tr>
<tr>
<td>4:10 pm</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

### The Cost of HCT and Cellular Therapies – From Symptoms, to Pockets, and Beyond

**MODERATORS:** Minoo Battiwalla, MD, MS and Gabriela Rondon, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:25 pm</td>
<td>Choosing Wisely in HCT and Its Applicability to Novel Cellular Therapies</td>
<td>Sita Bhella, MEd, MD</td>
</tr>
<tr>
<td>4:45 pm</td>
<td>Are CAR T Cells and Novel Cellular Therapies Cost-effective?</td>
<td>John K. Lin, MD</td>
</tr>
<tr>
<td>5:05 pm</td>
<td>The Short and Long-Term Costs of Critical Illness After HCT and Cellular Therapies</td>
<td>Christine Duncan, MD</td>
</tr>
<tr>
<td>5:25 pm</td>
<td>Impact of Financial and Socioeconomic Burden on HCT Outcomes</td>
<td>Kira Bona, MD, MPH</td>
</tr>
<tr>
<td>5:45 pm</td>
<td>Importance of Standardizing Cause-specific Death Adjudication After HCT and Cellular Therapies</td>
<td>Theresa Hahn, PhD</td>
</tr>
<tr>
<td>6:05 pm</td>
<td>Q&amp;A with Speakers</td>
<td></td>
</tr>
</tbody>
</table>

### Networking Reception & Poster Abstract Session

Course attendees are invited to join the faculty for a networking reception and poster abstract session immediately following the conclusion of day one from 6:15-7:30 pm at Zuckerman Research center. Hors d’oeuvres and refreshments will be served.

---

### DAY 2 – SATURDAY, OCTOBER 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>Breakfast</td>
<td></td>
</tr>
</tbody>
</table>

### Morning Seminar/Debate

**MODERATORS:** Hillard Lazarus, MD, FACP and Kenneth R. Cooke, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Harmonizing VOD/SOS Diagnosis and Classification</td>
<td>Mitchell Cairo, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Richard J. Jones, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>George McDonald, MD</td>
</tr>
</tbody>
</table>

### Keynote Address

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:50 am</td>
<td>Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy</td>
<td>Bronwen E Shaw, MD, PhD</td>
</tr>
</tbody>
</table>

### Investigational Research in Toxicities – From Bench to Bedside

**MODERATORS:** Navneet S. Majhail, MBBS, MD, MS and Michael Scordo, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:35 am</td>
<td>Use of Non-Genotoxic Conditioning to Mitigate Regimen-Related Toxicity</td>
<td>Rajni Agarwal-Hashmi, MD</td>
</tr>
<tr>
<td>10:00 am</td>
<td>The Injured Endothelium in HCT Toxicities</td>
<td>Christopher Dandoy, MD, MS</td>
</tr>
<tr>
<td>10:25 am</td>
<td>Virus specific T cells to Mitigate Infectious Complications After HCT</td>
<td>Pawel Muranski, MD</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:05 am</td>
<td>Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies</td>
<td>Ami Bhatt, MD, PhD</td>
</tr>
<tr>
<td>11:25 am</td>
<td>Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies</td>
<td>Benjamin Laskin, MD, MS</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design</td>
<td>Shernan Holtan, MD</td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Q&amp;A with Speakers</td>
<td></td>
</tr>
</tbody>
</table>

### Keynote Address

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 pm</td>
<td>Preventing All-Cause Death after HCT - What Should be our Focus when Designing Trials?</td>
<td>Andrea Bacigalupo, MD</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Symposium Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
REGISTRATION FEES

<table>
<thead>
<tr>
<th>Category</th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, PharmDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Advanced Practice Providers, Nurses, Data Managers and Other Healthcare Providers</td>
<td>$200</td>
<td>$250</td>
</tr>
<tr>
<td>Residents, Fellows</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
<tr>
<td>Live Simulcast</td>
<td>--</td>
<td>$600</td>
</tr>
</tbody>
</table>

*Early registration rates available through August 31, 2019.
**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

REGISTER ONLINE:
mskcc.org/toxicities

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

Location & Accommodations
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: mskcc.org/cme

Accreditation
Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement
MSK designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Faculty Disclosure
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

IN COLLABORATION WITH
UNC Lineberger Comprehensive Cancer Center
American Society for Transplantation and Cellular Therapy (ASTCT)
MD Anderson Cancer Center
Cleveland Clinic
Vanderbilt-Ingram Cancer Center
University of Minnesota
Sarah Cannon Center for Blood Cancer
Johns Hopkins Sidney Kimmel Cancer Center

w: mskcc.org/cme
e: cme@mskcc.org